尿管腺癌的现代治疗方法。

IF 0.9 4区 医学 Q4 UROLOGY & NEPHROLOGY
Samih Taktak, Omar El-Taji, Vishwanath Hanchanale
{"title":"尿管腺癌的现代治疗方法。","authors":"Samih Taktak,&nbsp;Omar El-Taji,&nbsp;Vishwanath Hanchanale","doi":"10.1097/CU9.0000000000000189","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>We sought to evaluate modern diagnostic and treatment options for urachal adenocarcinoma (UAC) and to provide clarity regarding the available options and their outcomes for this poorly understood yet damaging disease.</p><p><strong>Material and methods: </strong>We conducted a systematic literature search in PubMed and Medline focusing on updated management of UAC.</p><p><strong>Results: </strong>Surgical intervention continues to be the mainstay of treatment for localized UAC. However, with the increased availability of molecular and genetic profiling, chemotherapy has consistently demonstrated promising response rates and survival outcomes, especially for a disease that commonly presents in a metastatic stage. The role of checkpoint inhibitors remains under investigation. Cross-sectional imaging is vital during postoperative surveillance. However, there may also be a role for the adoption of cystoscopy to detect bladder recurrence.</p><p><strong>Conclusions: </strong>Although the importance of surgical resection remains unchanged, improved survival outcomes with chemotherapy have been found in small retrospective studies. Randomized trial data are required to further assess the influence of systemic treatment as a primary or adjuvant therapy. Moreover, a stringent follow-up regimen incorporating evaluation for distant and local recurrence of UAC must be evaluated and adopted.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"17 3","pages":"188-192"},"PeriodicalIF":0.9000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/77/curr-urol-17-188.PMC10337813.pdf","citationCount":"0","resultStr":"{\"title\":\"Modern methods in managing urachal adenocarcinoma.\",\"authors\":\"Samih Taktak,&nbsp;Omar El-Taji,&nbsp;Vishwanath Hanchanale\",\"doi\":\"10.1097/CU9.0000000000000189\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>We sought to evaluate modern diagnostic and treatment options for urachal adenocarcinoma (UAC) and to provide clarity regarding the available options and their outcomes for this poorly understood yet damaging disease.</p><p><strong>Material and methods: </strong>We conducted a systematic literature search in PubMed and Medline focusing on updated management of UAC.</p><p><strong>Results: </strong>Surgical intervention continues to be the mainstay of treatment for localized UAC. However, with the increased availability of molecular and genetic profiling, chemotherapy has consistently demonstrated promising response rates and survival outcomes, especially for a disease that commonly presents in a metastatic stage. The role of checkpoint inhibitors remains under investigation. Cross-sectional imaging is vital during postoperative surveillance. However, there may also be a role for the adoption of cystoscopy to detect bladder recurrence.</p><p><strong>Conclusions: </strong>Although the importance of surgical resection remains unchanged, improved survival outcomes with chemotherapy have been found in small retrospective studies. Randomized trial data are required to further assess the influence of systemic treatment as a primary or adjuvant therapy. Moreover, a stringent follow-up regimen incorporating evaluation for distant and local recurrence of UAC must be evaluated and adopted.</p>\",\"PeriodicalId\":39147,\"journal\":{\"name\":\"Current Urology\",\"volume\":\"17 3\",\"pages\":\"188-192\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/77/curr-urol-17-188.PMC10337813.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/CU9.0000000000000189\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CU9.0000000000000189","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:我们试图评估尿管腺癌(UAC)的现代诊断和治疗方案,并为这种知之甚少但具有破坏性的疾病提供明确的可用选择及其结果。材料和方法:我们在PubMed和Medline上进行了系统的文献检索,重点是UAC的最新管理。结果:手术干预仍然是治疗局限性UAC的主要方法。然而,随着分子和基因谱分析的增加,化疗一直显示出有希望的反应率和生存结果,特别是对于通常出现在转移期的疾病。检查点抑制剂的作用仍在研究中。横断面成像在术后监测中至关重要。然而,采用膀胱镜检查也可能对膀胱复发有一定的作用。结论:尽管手术切除的重要性保持不变,但在小型回顾性研究中发现化疗可改善生存结果。需要随机试验数据来进一步评估全身治疗作为主要或辅助治疗的影响。此外,必须评估和采用严格的随访方案,包括远处和局部UAC复发的评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Modern methods in managing urachal adenocarcinoma.

Modern methods in managing urachal adenocarcinoma.

Modern methods in managing urachal adenocarcinoma.

Modern methods in managing urachal adenocarcinoma.

Objectives: We sought to evaluate modern diagnostic and treatment options for urachal adenocarcinoma (UAC) and to provide clarity regarding the available options and their outcomes for this poorly understood yet damaging disease.

Material and methods: We conducted a systematic literature search in PubMed and Medline focusing on updated management of UAC.

Results: Surgical intervention continues to be the mainstay of treatment for localized UAC. However, with the increased availability of molecular and genetic profiling, chemotherapy has consistently demonstrated promising response rates and survival outcomes, especially for a disease that commonly presents in a metastatic stage. The role of checkpoint inhibitors remains under investigation. Cross-sectional imaging is vital during postoperative surveillance. However, there may also be a role for the adoption of cystoscopy to detect bladder recurrence.

Conclusions: Although the importance of surgical resection remains unchanged, improved survival outcomes with chemotherapy have been found in small retrospective studies. Randomized trial data are required to further assess the influence of systemic treatment as a primary or adjuvant therapy. Moreover, a stringent follow-up regimen incorporating evaluation for distant and local recurrence of UAC must be evaluated and adopted.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Urology
Current Urology Medicine-Urology
CiteScore
2.30
自引率
0.00%
发文量
96
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信